Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 7/20 | 0.33 |
| ▸ | RAB9A | P51151 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198903 | 0.81 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM3TRPM8 | |
| SCHEMBL13644713 | 0.77 | MEN1 (0.43) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL9299188 | 0.75 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM3TRPM8 | |
| SCHEMBL12194651 | 0.75 | SMN1; SMN2 (0.33) | NPC1RAB9AALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL6607334 | 0.75 | — | — | |
| SCHEMBL2124282 | 0.73 | — | — | |
| SCHEMBL10200350 | 0.70 | TRPM8 (0.45) | CHRM2CHRM4CHRM5CHRM3TRPM8 | |
| SCHEMBL13479963 | 0.70 | — | — | |
| SCHEMBL1185435 | 0.69 | — | — | |
| SCHEMBL15872012 | 0.68 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8247532-B2 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | PEPD, CTRL, CTSC | CHRM2 4885/4885CHRM4 4882/4885CHRM5 4881/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | CHRM2 1350/4885CHRM4 1502/4885CHRM5 2258/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | CHRM2 4837/4885CHRM4 4856/4885CHRM5 4851/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | CHRM2 4837/4885CHRM4 4856/4885CHRM5 4851/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | CHRM2 1350/4885CHRM4 1502/4885CHRM5 2258/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | CHRM2 4837/4885CHRM4 4856/4885CHRM5 4851/4885 |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | PEPD, CTRL, CTSC | CHRM2 4885/4885CHRM4 4882/4885CHRM5 4881/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | CHRM2 4803/4885CHRM4 4822/4885CHRM5 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.